Details

Autor(en) / Beteiligte

• Grobben, Marloes
• van der Straten, Karlijn
• Brouwer, Philip Jm
• Brinkkemper, Mitch
• Maisonnasse, Pauline
• Dereuddre-Bosquet, Nathalie
• Appelman, Brent
• Lavell, Ah Ayesha
• van Vught, Lonneke A
• Burger, Judith A
• Poniman, Meliawati
• Oomen, Melissa
• Eggink, Dirk
• Bijl, Tom Pl
• van Willigen, Hugo Dg
• Wynberg, Elke
• Verkaik, Bas J
• Figaroa, Orlane Ja
• de Vries, Peter J
• Boertien, Tessel M
• Bomers, Marije K
• Sikkens, Jonne J
• Le Grand, Roger
• de Jong, Menno D
• Prins, Maria
• Chung, Amy W
• de Bree, Godelieve J
• Sanders, Rogier W
• van Gils, Marit J

Titel

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination

Ist Teil von

• eLife, 2021-11, Vol.10

Ort / Verlag

England: eLife Science Publications, Ltd

Erscheinungsjahr

2021

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.